Sanos Clinic GmbH
- Address
- Kokkolastrasse 1, Ost, 40882 Ratingen, Germany
Nervous System Diseases and Alzheimer’s Disease
At Sanos Clinic GmbH in Ratingen, clinical research in neurology focuses on nervous system diseases, with a strong emphasis on Alzheimer’s disease. The trials are designed to assess the safety and tolerability of new treatment approaches and to explore whether they may help improve symptoms and disease management in people with mild to moderate memory loss and cognitive decline.
- Evaluating a new therapy for Alzheimer’s disease
- Studying safety, tolerability, and early signs of benefit in mild to moderate dementia
- Exploring potential ways to support brain function and patient care
This research reflects the site’s role in advancing practical treatment options for neurodegenerative disorders through patient-focused clinical studies.
Cardiovascular Diseases and Atherosclerotic Cardiovascular Disease
The site also conducts research in cardiovascular diseases, especially atherosclerotic cardiovascular disease, with trials aimed at reducing the risk of serious heart, stroke, and vascular complications. These studies are intended to determine how well a new treatment can help prevent major events and improve outcomes for people with established disease or elevated risk.
- Testing a therapy for heart and blood vessel disease
- Assessing prevention of heart attack, stroke, and other major vascular events
- Measuring treatment effectiveness in patients at high risk of cardiovascular complications
By combining prevention-focused research with clinical care expertise, Sanos Clinic GmbH contributes to studies that aim to lower the burden of serious cardiovascular events.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sanos Clinic GmbH
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Baxdrostat and Dapagliflozin on Heart Failure Incidence and Cardiovascular Mortality in High-Risk Patients: A Phase III Randomized Controlled Trial | AstraZeneca AB | Phase III | Recruiting | May 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE | 1 | Unknown | 2025-08-25 | 2025-08-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.